http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Association between Gastric pH and Helicobacter pylori Infection in Children
Seo, Ji-Hyun,Park, Heung Keun,Park, Ji Sook,Yeom, Jung Sook,Lim, Jae-Young,Park, Chan-Hoo,Woo, Hyang-Ok,Youn, Hee-Shang,Jun, Jin-Su,Ko, Gyung-Hyuck,Baik, Seung-Chul,Lee, Woo-Kon,Cho, Myung-Je,Rhee, Kw The Korean Society of Pediatric Gastroenterology 2015 Pediatric gastroenterology, hepatology & nutrition Vol.18 No.4
Purpose: To assess gastric pH and its relationship with urease-test positivity and histological findings in children with Helicobacter pylori infection. Methods: Fasting gastric juices and endoscopic antral biopsy specimens were collected from 562 children and subjected to the urease test and histopathological examination. The subjects were divided into 3 age groups: 0-4, 5-9, and 10-15 years. The histopathological grade was assessed using the Updated Sydney System, while the gastric juice pH was determined using a pH meter. Results: The median gastric juice pH did not differ significantly among the age groups (p=0.655). The proportion of individuals with gastric pH >4.0 was 1.3% in the 0-4 years group, 6.1% in the 5-9 years group, and 8.2% in 10-15 years (p=0.101). The proportions of moderate and severe chronic gastritis, active gastritis, and H. pylori infiltration increased with age (p<0.005). Urease-test positivity was higher in children with hypochlorhydria (77.8%) than in those with normal gastric pH (31.7%) (p<0.001). Chronic and active gastritis were more severe in the former than the latter (p<0.001), but the degree of H. pylori infiltration did not differ (20.9% vs. 38.9%; p=0.186). Conclusion: Gastric pH while fasting is normal in most children regardless of age. Urease-test positivity may be related to hypochlorhydria in children, and hypochlorhydria is in turn related to H. pylori infection.
Late Recurrent Coronary Artery Occlusion After Stenting in a Patient Diagnosed as Polycythemia Vera
( Hae Geun Song ),( Jae Hyun Cho ),( Young Jin Choi ),( Seong Hwan Kim ),( Eung Ju Kim ),( Hyo Jung Kim ),( Woo Jung Park ),( Seung Hyuk Choi ),( Kyoo Rok Han ),( Dong Jin Oh ),( Chong Yun Rhim ),( Kw 대한내과학회 2005 대한내과학회 추계학술대회 Vol.69 No.10
간세포암종 환자에서 간동맥화학색전술 후 급성 신부전의 빈도 및 위험인자
장병국 ( Byoung Kuk Jang ),이승현 ( Seung Hyun Lee ),정우진 ( Woo Jin Chung ),박경식 ( Kyung Sik Park ),조광범 ( Kwang Bum Cho ),황재석 ( Jae Seok Hwang ),김영환 ( Young Hwan Kim ),최진수 ( Jin Soo Choi ),권중혁 ( Jung Hyeok Kw 대한간학회 2008 Clinical and Molecular Hepatology(대한간학회지) Vol.14 No.2
The N-Degron Pathway Mediates ER-phagy
Ji, Chang Hoon,Kim, Hee Yeon,Heo, Ah Jung,Lee, Su Hyun,Lee, Min Ju,Kim, Su Bin,Srinivasrao, Ganipisetti,Mun, Su Ran,Cha-Molstad, Hyunjoo,Ciechanover, Aaron,Choi, Cheol Yong,Lee, Hee Gu,Kim, Bo Yeon,Kw Elsevier 2019 Molecular cell Vol.75 No.5
<P><B>Summary</B></P> <P>The endoplasmic reticulum (ER) is susceptible to wear-and-tear and proteotoxic stress, necessitating its turnover. Here, we show that the N-degron pathway mediates ER-phagy. This autophagic degradation initiates when the transmembrane E3 ligase TRIM13 (also known as RFP2) is ubiquitinated via the lysine 63 (K63) linkage. K63-ubiquitinated TRIM13 recruits p62 (also known as sequestosome-1), whose complex undergoes oligomerization. The oligomerization is induced when the ZZ domain of p62 is bound by the N-terminal arginine (Nt-Arg) of arginylated substrates. Upon activation by the Nt-Arg, oligomerized TRIM13-p62 complexes are separated along with the ER compartments and targeted to autophagosomes, leading to lysosomal degradation. When protein aggregates accumulate within the ER lumen, degradation-resistant autophagic cargoes are co-segregated by ER membranes for lysosomal degradation. We developed synthetic ligands to the p62 ZZ domain that enhance ER-phagy for ER protein quality control and alleviate ER stresses. Our results elucidate the biochemical mechanisms and pharmaceutical means that regulate ER homeostasis.</P> <P><B>Highlights</B></P> <P> <UL> <LI> The autophagic adaptor p62 mediates autophagic degradation of the ER (ER-phagy) </LI> <LI> The ER membrane E3 ligase TRIM13 is a ubiquitin-dependent ER-phagy receptor to p62 </LI> <LI> N-terminal arginylation is an ER-phagy degron via binding to the ZZ domain of p62 </LI> <LI> p62-TRIM13-Nt-Arg circuit mediates ER protein quality control and homeostasis </LI> </UL> </P> <P><B>Graphical Abstract</B></P> <P>[DISPLAY OMISSION]</P>
( Tae Hee Lee ),( Joon Seong Lee ),( Su Jin Hong ),( Ji Sung Lee ),( Seong Ran Jeon ),( Wan Jung Kim ),( Hyun Gun Kim ),( Joo Young Cho ),( Jin Oh Kim ),( Jun Hyung Cho ),( Mi Young Kim ),( Soon Ha Kw 대한소화기기능성질환·운동학회 2014 Journal of Neurogastroenterology and Motility (JNM Vol.20 No.3
Background/Aims Impedance analysis using high-resolution impedance manometry (HRIM) enables the recognition of pharyngeal residue in patients with oropharyngeal dysphagia. The aims of this study were to evaluate appropriate criteria for impedance analysis in a large patient cohort, as well as the diagnostic accuracy and agreement of analysis performed by HRIM trainees. Methods We reviewed 33 controls (13 males; median age, 61.2 years) and 104 oropharyngeal dysphagia patients (61 males; median age, 70.4 years) who underwent a flexible endoscopic evaluation of swallowing study (FEES) and HRIM. Two experts compared the pharyngeal residue on FEES and impedance color pattern at 1,000, 1,500 and 2,000 Ω of the impedance bar. Three trainees were given a 60 minutes tutorial to determine the diagnostic accuracy and agreement of this analysis. Results The diagnostic sensitivity of experts for predicting liquid residue was 73.1% for 1,000 Ω, 96.2% for 1,500 Ω and 100% for 2,000 Ω. Significantly higher sensitivity was observed at 1,500 Ω compared to 1,000 Ω (P < 0.001). The diagnostic specificity of experts for liquid residue was 98.3% for 1,000 Ω, 96.6% for 1,500 Ω and 83.1% for 2,000 Ω. There was a higher specificity at 1,500 Ω compared to 2,000 Ω (P = 0.008). The κ value among the 3 trainees was 0.89 and the diagnostic accuracy of the trainees for liquid residue was comparable to that of the experts. Conclusions The impedance analysis at 1,500 Ω provides more accurate information for the detection of liquid residue, irrespective of the level of expertise. (J Neurogastroenterol Motil 2014;20:362-370)
Bedside Estimation of the Length of Nares-Vocal Cord in Children
이영은,신터전,김종철,이상훈,장기택,김정욱,김영재,현홍근,한효조,김현정,서광석,Lee, Young-Eun,Shin, Teo-Jeon,Kim, Chong-Chul,Lee, Sang-Hoon,Jang, Ki-Taeg,Kim, Jung-Wook,Kim, Youmg-Jae,Hyun, Hong-Keun,Han, Hyo-Jo,Kim, Hyun-Jeong,Seo, Kw The Korean Dental Society of Anesthsiology 2011 Journal of Dental Anesthesia and Pain Medicine Vol.11 No.2
배경: 협조가 불가능하거나 진정법 하 치과치료가 여의치 않을 경우 전신마취 하 치료를 계획하게 된다. 하지만 전신마취 하 치료시 기관내 삽관이 여의치 않은 경우를 종종 경험하게 된다. 이와같은 경우 기관지경을 이용한 기관내 삽관을 시행한다. 기관지 내시경을 환자의 성문에 근접하게 전진시킬 경우 기관지 내시경 하 시야확보가 용이한 점을 감안 시 비공 - 성대간 거리를 예측하는 것은 매우 유용할 것으로 생각된다. 또한 비공 - 성대간 거리를 추정하게 되면 맹목적 비강내 기관내 삽관을 하는데도 도움이 된다. 방법: 본 연구는 전신마취하 치과치료가 예정되어 있는 62명의 소아환자들을 대상으로 하여 신체변수와 비공 - 성대거리와의 관계를 확인해보고자 하였다. 선형회귀분석을 시행하여 다음과 같은 결론을 도출하였다. 결과: 소아환자들에 있어 비공 - 성대간 거리는 환아의 신장, 체중, 연령 등과 상관관계를 나타내었다. 비공 - 성대간 거리와 상관관계를 보인 변수들 중 에서 신장과의 상관계수가 가장 높았다. 선형회귀분석을 통해 비공 - 성대간 거리를 예측하는 다음과 같은 회귀식을 구하였다. 비공 - 성대간 거리 = (4.8 + 신장(cm)) ${\times}$ 0.07 고찰: 본 연구에서 구해진 회귀식을 이용하여 기도유지가 어려운 소아의 기도유지 하는데 큰 도움이 될 것으로 생각된다.
( Ki Tae Yoon ),( Youn Jae Lee ),( Seung Ha Park ),( Young Seok Kim ),( Jeong Won Jang ),( Jun Yong Park ),( June Sung Lee ),( Jeong Heo ),( Mong Cho ),( Sung Jae Park ),( Eun Uk Jung ),( Jung Hyun Kw 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Standard treatment in patients with hepatitis C virus (HCV) genotype 2 is the combination of peginterferon (pegIFN) α and ribavirin (RBV) for 24 weeks. There were several studies to investigate whether a shorter course treatment is as effective as a standard 24-week treatment. In spite of the short duration, some studies have shown the sufficient efficacy, especially in patients who had a rapid virologic response (RVR) at 4 weeks. But some other studies have reported conflicting results. We investigate the 16 weeks of treatment with pegIFN and weight-based RBV is as effective as 24 weeks in patients who achieve RVR with genotype 2 chronic hepatitis C (CHC). Methods: This is a prospective, randomized, controlled study. Patients with genotype 2 CHC were treated with pegIFN α-2a (180 μg/week) and weight-based RBV 800-1200 mg/day. The only patients who achieve RVR at week 4 were randomized in a 1:1 ratio to 16 or 24 weeks. We are conducting the study and will enroll a total of 164 patients. Now, 84 patients who have completed the study are included in this interim analysis. The primary end point was sustained virologic response (SVR) which was defined as not detectable HCV RNA at 24 weeks after the completion of treatment. Results: There was no statistically difference in SVR (90.7% in 16 weeks vs. 92.7% in 24 weeks, p=0.999). End of treatment virologic reponse was 100% in the 16 weeks group and 97.6% in the 24 weeks group (p=0.488). Relapse rate was 9.3% in the 16 weeks group and 4.9% in the 24 weeks group (p=0.676). Conclusions: A shorter course of therapy for 16 weeks with pegIFN α-2a and weigh-based RBV is as effective as a 24 weeks treatment in patients who achieve RVR with genotype 2 CHC.
( Ki Tae Yoon ),( Youn Jae Lee ),( Seung Ha Park ),( Young Seok Kim ),( Jeong Won Jang ),( Jun Yong Park ),( June Sung Lee ),( Jeong Heo ),( Mong Cho ),( Sung Jae Park ),( Eun Uk Jung ),( Jung Hyun Kw 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Standard treatment in patients with hepatitis C virus (HCV) genotype 2 is the combination of peginterferon (pegIFN) α and ribavirin (RBV) for 24 weeks. There were several studies to investigate whether a shorter course treatment is as effective as a standard 24-week treatment. In spite of the short duration, some studies have shown the sufficient efficacy, especially in patients who had a rapid virologic response (RVR) at 4 weeks. But some other studies have reported conflicting results. We investigate the 16 weeks of treatment with pegIFN and weight-based RBV is as effective as 24 weeks in patients who achieve RVR with genotype 2 chronic hepatitis C (CHC). Methods: This is a prospective, randomized, controlled study. Patients with genotype 2 CHC were treated with pegIFN α-2a (180 μg/week) and weight-based RBV 800-1200 mg/day. The only patients who achieve RVR at week 4 were randomized in a 1:1 ratio to 16 or 24 weeks. We are conducting the study and will enroll a total of 164 patients. Now, 84 patients who have completed the study are included in this interim analysis. The primary end point was sustained virologic response (SVR) which was defined as not detectable HCV RNA at 24 weeks after the completion of treatment. Results: There was no statistically difference in SVR (90.7% in 16 weeks vs. 92.7% in 24 weeks, p=0.999). End of treatment virologic reponse was 100% in the 16 weeks group and 97.6% in the 24 weeks group (p=0.488). Relapse rate was 9.3% in the 16 weeks group and 4.9% in the 24 weeks group (p=0.676). Conclusions: A shorter course of therapy for 16 weeks with pegIFN α-2a and weigh-based RBV is as effective as a 24 weeks treatment in patients who achieve RVR with genotype 2 CHC.